Good distribution practice
||This article includes a list of references, related reading or external links, but its sources remain unclear because it lacks inline citations. (December 2014) (Learn how and when to remove this template message)|
Good distribution practice (GDP) deals with the guidelines for the proper distribution of medicinal products for human use. GDP is a quality warranty system, which includes requirements for purchase, receiving, storage and export of drugs intended for human consumption.
GDP regulates the division and movement of pharmaceutical products from the premises of the manufacturer of medicinal products, or another central point, to the end user thereof, or to an intermediate point by means of various transport methods, via various storage and/or health establishments.
- In Europe GDP is based on the Directive of the Board of the European Community 92/25/EEC regarding the wholesale distribution of drugs for human consumption.
- In US GMP is based on the Code of Federal Regulations 21 CFR 210/211, and USP 1079.
- European Medicines Agency (EMA)
- Good manufacturing practice
- Japan Ministry of Health
- Packaging and labeling
- Prescription Drug Marketing Act (PDMA) of the USA
- WHO: Good Distribution Practices (GDP) for Pharmaceutical Products
- Demo applet of an evolutionary algorithm for optimizing goods distribution problems (VRPTW and TSP)
- Guidelines on Good Distribution Practice of Medicinal Products for Human Use (94/C 63/03)
- Counterfeit Drugs (FDA)
- Radiofrequency Identification Feasibility Studies and Pilot Programs for Drugs (FDA)
- GDP Guidelines of 7 March 2013 (Eudralex)
- Guidelines on Good Distribution Practice (NPCB/Malaysia)